Related Experiment Video

Updated: May 13, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

[In silico drug discovery and SBDD]

Teruki Honma1

  • 1Structure-based Drug Design Research Team, Systems and Structural Biology Center, RIKEN.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2013
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Experiment Videos

Last Updated: May 13, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Articles linked to this work by shared authors, journal, and citation graph.

Crystallographic snapshots of Trypanosoma cruzi aspartate transcarbamoylase including catalytic intermediates suggest an ordered Bi-Bi reaction mechanism.

Scientific reports·2026

Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability.

JACS Au·2026

Empowering federated learning for robust compound-protein interaction prediction across heterogeneous cross-pharma domains.

Journal of cheminformatics·2026

A Dual-Target-Based Screening Strategy for Anti-SARS-CoV-2 Active Compounds Enabling the Identification of Macrocyclic Peptide Natural Products: Chloropeptins.

Journal of natural products·2025

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14).

Blood neoplasia·2025

Quantitative Structure-Activity Relationships for Human Galectin-3 Inhibitors: Insights from Quantum Chemical Interaction Energy Terms.

Journal of chemical information and modeling·2025

Total Synthesis of Paliurine E by a Highly Convergent Block Approach.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Ring-opening simplification of thiazolyl-pyrazoline-triazole hybrids: synthesis, SAR and antifolate mechanism against Leishmania major.

RSC medicinal chemistry·2026

Metal-drug coordinated nanozymes for ROS scavenging and Kupffer cell polarization to alleviate drug-induced liver injury.

Acta pharmaceutica Sinica. B·2026

Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders.

Acta pharmaceutica Sinica. B·2026

SASH1 as a Context-Dependent Multi-Docking Scaffold Linking Receptor Signaling to Cytoskeletal Dynamics.

International journal of molecular sciences·2026

Biological Evaluation, Molecular Docking, and in Ovo Hatchability Assessment of Selected Mannich-Type 1,2,4-Triazol-5-one Derivatives.

International journal of molecular sciences·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us